Paul B. Watkins

Safety biomarkers for drug-induced liver injury – current status and future perspectives

P. Watkins, B. K. Park, D. Antoine, 2014 .

Refining Liver Safety Risk Assessment: Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical Trials

S. Siler, T. Parry, B. Howell, 2017, Clinical pharmacology and therapeutics.

Drug‐induced liver injury: Advances in mechanistic understanding that will inform risk management

M. Mosedale, P. Watkins, Paul B. Watkins, 2017, Clinical pharmacology and therapeutics.

Drug-induced liver injury

P. Watkins, N. Chalasani, R. Andrade, 2019, Nature Reviews Disease Primers.

COMT inhibitors and liver toxicity.

P. Watkins, Paul B. Watkins, 2000, Neurology.

Mechanisms of Drug‐induced Liver Injury

P. Watkins, Paul B. Watkins, 2011 .

Assessing Liver Effects of Cannabidiol and Valproate Alone and in Combination Using Quantitative Systems Toxicology

Vinal V. Lakhani, B. Howell, Grant T. Generaux, 2023, Clinical pharmacology and therapeutics.

A Mechanistic Model of Drug-Induced Liver Injury Aids the Interpretation of Elevated Liver Transaminase Levels in a Phase I Clinical Trial

P. Watkins, S. Siler, P B Watkins, 2014, CPT: pharmacometrics & systems pharmacology.